Accelerate Diagnostics, Tucson, Arizona, USA
SRS Optical Imaging
Diagnosis of Sepsis
Accelerate is developing a compact instrument for the rapid diagnosis of sepsis. Accelerate’s novel optical imaging technology aims to rapidly identify infectious microbes to help clinicians speed treatment of patients with sepsis or at risk for sepsis. The CARB-X award provides support for research into the possible application of fiber optic technology, called Stimulated Raman Spectroscopy (SRS), to identify bacteria. Bacterial identification could potentially be within 15 minutes from a positive blood culture with minimal sample processing. The technology has demonstrated high sensitivity and specificity and is able to identify a wide range of pathogens which is currently not possible with panel tests. A rapid test is especially important for sepsis treatment where every hour of delay in appropriate treatment reduces the chance of survival.
Current Development Stage: Feasibility
CARB-X Investment: Initial investment of up to $578,000 with potential milestone payments of up to $2.1 million
Initial CARB-X Investment Date: March 1, 2021